Berkow E, Lockhart S. Fluconazole resistance in Candida species: a current perspective. Infec and Drug Resistance 2017;10:237-245.
Borman AM, Johnson EM. Name Changes for Fungi of Medical Importance, 2018 to 2019. J Clin Microbiol. 2021 Feb; 59(2):1-8.
Borman AM, Muller J, Quantick-Walsh J, et al. Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom. Antimicrobial Agents and Chemotherapy 2019 Aug;63(8):1-12.
Borman AM, Muller J, Quantick-Walsh J, et al. MIC distributions for amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine and anidulafungin and 35 uncommon pathogenic yeast species from the UK determined using the CLSI broth microdilution method. J Antimicrob Chemotherapy 2020;75:1194-1205.
Bowen AC, Carapetis JR, Currie BJ, et al. Sulfamethoxazole-trimethoprim (cotrimoxazole) for skin and soft tissue infections including impetigo, cellulitis, and abscess. OFID 2017:1-7.
Bowen AC, Lilliebridge RA, Tong SYC, et al. Is Streptococcus pyogenes resistant or susceptible to trimethoprim-sulfamethoxazole? J Clin Microbiol 2012;50:4067-72.
Cho C, Shields RK, Kline EG, et al. In vitro activity of clindamycin, doxycycline, and trimethoprim/sulfamethoxazole against clinical isolates of β-hemolytic Streptococcus spp. via BD Phoenix and broth microdilution. Antimicrob Stewardship Healthcare Epidemiol 2023;3, e238:1-3. doi:10.1017/ash.2023.515
Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination. Pharmacotherapy 2015;35:701-15.
Craig WA, Andes DR. In vivo activities of ceftolozane, a new cepahalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 2013;57:1577-82.
Durukan D, Read TRH, Murray G, et al. Resistance-guided antimicrobial therapy using doxycycline–moxifloxacin and doxycycline–2.5g azithromycin for the treatment of Mycoplasma genitalium infection: efficacy and tolerability. Clin Infect Dis 2020;71:1461-8.
Farrell DJ, Flamm RK, Sader HS, et al. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob Agents Chemother 2013;57:6305-10.
Gilbert DN, Moellering RC, Eliopoulos GM, eds. The Sanford guide to antimicrobial therapy 2018. Sperryville, VA: Antimicrobial Therapy, Inc. 2018.
Gratrix J, Plitt S, Turnbull L, et al. Prevalence and antibiotic resistance of Mycoplasma genitalium among STI clinic attendees in Western Canada: a cross-sectional analysis. BMJ Open 2017;7:e016300. doi:10.1136/bmjopen-2017-016300.
Grayson ML, Crowe SM, McCarthy JS, et al, eds. Kucers’ the use of antibiotics 6th edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. 2010 CRC Press, Boca Raton FL.
Horner P, Donders G, Cusini M, et al. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? - a position statement from the European STI Guidelines Editorial Board. J European Academy of Dermatology and Venereology 2018. DOI: 10.1111/jdv.15146.
Li et al. Int J STD AIDS 2017.
Manhart LE. Clin Infect Dis 2011;53 Suppl 3:S129.
Meygret A, Le Roy C, Renaudin H, et al. Tetracycline and fluoroquinolone resistance in clinical Ureaplasma spp. and Mycoplasma hominis isolates in France between 2010 and 2015. J Antimicrob Chemother 2018;73:2696.
Scott LJ. Ceftolozane/tazobactam: a review in complicated intra-abdominal and urinary tract infections. Drugs 2016;76:231-42.
Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 2015;60:1462-71.
Sucher AJ, Chahine EB, Cogan P, et al. Ceftolozane/tazobactam: a new cephalosporin and β-lactamase inhibitor combination. Ann Pharmacother 2015;49:1046-56.
Versalovic J, Carroll KC, Funke G, et al. Manual of clinical microbiology, 10th edition, 2011. Washington, DC: ASM Press 2011.
Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane/ tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015;385:1949-56.
Xiao et al. Int J Antimicrob Agents 2011;37:377.
Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs 2014;74:31-51.
